✦ LIBER ✦

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

✍ Scribed by Bhupendra Khatri; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Ludwig Kappos; Xavier Montalban; Jean Pelletier; Tracy Stites; Stacy Wu; Fred Holdbrook; Lixin Zhang-Auberson; Gordon Francis; Jeffrey A Cohen

Book ID: 114409802
Publisher: The Lancet
Year: 2011
Tongue: English
Weight: 228 KB
Volume: 10
Category: Article
ISSN: 1474-4465
DOI: 10.1016/s1474-4422(11)70099-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PND1 Estimating Net Health Benefits Of I

PND1 Estimating Net Health Benefits Of Intramuscular Interferon Beta-1A And Fingolimod In Treating Patients With Relapsing-Remitting Multiple Sclerosis

✍ S.M. Szabo; C. Dembek; P. Moore; L.A. White; H. Wijaya; A.R. Levy 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Randomised double-blind placebo-controll

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

✍ George C Ebers 📂 Article 📅 1998 🏛 The Lancet 🌐 English ⚖ 97 KB

Methylprednisolone in combination with i

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial

✍ Mads Ravnborg; Per Soelberg Sørensen; Magnus Andersson; Elisabeth G Celius; Pete 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 374 KB

Comparison of interferon beta products a

Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis

✍ M. Etemadifar; M. Janghorbani; V. Shaygannejad 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 264 KB

Efficacy and safety of subcutaneous inte

Efficacy and safety of subcutaneous interferon beta-1a in relapsing–remitting multiple sclerosis: Further outcomes from the IMPROVE study

✍ Nicola De Stefano; Maria Pia Sormani; Bettina Stubinski; Gregg Blevins; Jelena S 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 369 KB

Alemtuzumab versus interferon beta 1a as

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

✍ Jeffrey A Cohen; Alasdair J Coles; Douglas L Arnold; Christian Confavreux; Edwar 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 334 KB